Skip to content
Politically.com Search all
Menu

2026 · 2nd Quarter (Apr 1 - June 30)

GENENTECH

Filed by THE MCMANUS GROUP.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
2nd Quarter - Report
Posted
Jul 20, 2026
Income
$50,000.00
Expenses
Not reported
Client
GENENTECH
Filing UUID
5b2a70d1-e902-4bb8-bf5e-0be01636255e
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs, including Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 4299). Policies related to the Most Favored Nation Drug Pricing Model.

Literal federal measure citations: H.R. 4299

HCR · Health Issues

Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.

TAX · Taxation/Internal Revenue Code

Issues related to tax exempt hospitals and charity care. Issues related to the Tax Exempt Hospital Transparency Act (H.R. 9504).

Literal federal measure citations: H.R. 9504

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.